BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ercaliskan A, Eskazan AE. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia: Impact of Transcript Type on TKI Outcomes in CML. Cancer 2018;124:3806-18. [DOI: 10.1002/cncr.31408] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Chen K, Ruan Y, Tian K, Xiong P, Xia N, Li J, Huang W, Cao F, Chen Q. Impact of BCR-ABL1 Transcript Type on Outcome in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors: A Pairwise and Bayesian Network Meta-Analysis. Front Oncol 2022;12:841546. [PMID: 35223524 DOI: 10.3389/fonc.2022.841546] [Reference Citation Analysis]
2 Patel KD, De M, Jethva DD, Rathod BS, Patel PS. Alterations in Sialylation Patterns are Significantly Associated with Imatinib Mesylate Resistance in Chronic Myeloid Leukemia. Arch Med Res 2021:S0188-4409(21)00125-9. [PMID: 34275666 DOI: 10.1016/j.arcmed.2021.06.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Mughal TI, Psaila B, DeAngelo DJ, Saglio G, Van Etten RA, Radich JP. Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021. Haematologica 2021;106:1787-93. [PMID: 33657787 DOI: 10.3324/haematol.2020.267252] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Massimino M, Tirrò E, Stella S, Manzella L, Pennisi MS, Romano C, Vitale SR, Puma A, Tomarchio C, Di Gregorio S, Antolino A, Di Raimondo F, Vigneri P. Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts. Front Pharmacol 2021;12:669469. [PMID: 34276365 DOI: 10.3389/fphar.2021.669469] [Reference Citation Analysis]
5 Breccia M, Efficace F, Scalzulli E, Ciotti G, Maestrini G, Colafigli G, Martelli M. Measuring prognosis in chronic myeloid leukemia: what's new? Expert Rev Hematol 2021;14:577-85. [PMID: 34075852 DOI: 10.1080/17474086.2021.1938534] [Reference Citation Analysis]
6 Soriani S, Guido V, Bertani G, Cesana C, Motta V, De Canal G, De Paoli E, Veronese S, Bonoldi E, Romitti L. BCR/ABL1 fluorescence in situ hybridization fusion signals on both copies of chromosome 22 in a Philadelphia-masked chronic myeloid leukemia case: implication for the therapy. Hematol Rep 2021;13:8795. [PMID: 33824712 DOI: 10.4081/hr.2021.8795] [Reference Citation Analysis]
7 Nachi M, Kihel I, Entasoltane B, Brahimi M, Yafour N, Guella D, Abed A, Bekadja MA. Impact of the major BCR-ABL1 transcript type on clinical and biological parameters and molecular response in patients with chronic myeloid leukemia. Hematol Oncol Stem Cell Ther 2020:S1658-3876(20)30145-X. [PMID: 32971032 DOI: 10.1016/j.hemonc.2020.08.003] [Reference Citation Analysis]
8 Kucukyurt S, Yagiz Ozogul Y, Ercaliskan A, Kabasakal L, Eskazan AE. Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor. Cancer Rep (Hoboken) 2020;3:e1282. [PMID: 32896091 DOI: 10.1002/cnr2.1282] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Mulas O, Caocci G, Annunziata M, Martino B, Luciano L, Castagnetti F, Pregno P, Galimberti S, Albano F, Orlandi EM, Sgherza N, Iurlo A, Bonifacio M, Binotto G, Gozzini A, Bocchia M, Abruzzese E, Fozza C, Simula MP, De Gregorio F, Gugliotta G, Pirillo F, Baratè C, Attolico I, Elena C, Cattaneo D, Scaffidi L, Sicuranza A, Trawinska MM, Scalzulli E, Foà R, Breccia M, La Nasa G. Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib. Hematol Oncol 2020;38:607-10. [PMID: 32602167 DOI: 10.1002/hon.2765] [Reference Citation Analysis]
10 Genthon A, Nicolini FE, Huguet F, Colin-Gil C, Berger M, Saugues S, Janel A, Hayette S, Cohny-Makhoul P, Cadoux N, Cayuela JM, Campos L, Guyotat D, Flandrin-Gresta P. Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib. Oncotarget 2020;11:2560-70. [PMID: 32655840 DOI: 10.18632/oncotarget.27652] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Özgür Yurttaş N, Eşkazan AE. Novel therapeutic approaches in chronic myeloid leukemia. Leuk Res 2020;91:106337. [PMID: 32200189 DOI: 10.1016/j.leukres.2020.106337] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
12 Baccarani M, Rosti G, Soverini S. Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type. Leukemia. 2019;33:2358-2364. [PMID: 31455852 DOI: 10.1038/s41375-019-0562-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
13 Zhang X, Guo X. Coexistence of BCR/ABL1 p190 transcript and CEBPA double mutations in de novo acute myeloid leukemia. Leuk Lymphoma 2019;60:2844-6. [PMID: 31050567 DOI: 10.1080/10428194.2019.1608532] [Reference Citation Analysis]
14 Greenfield G, McMullan R, Robson N, McGimpsey J, Catherwood M, McMullin MF. Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia. BMC Hematol 2019;19:7. [PMID: 31073408 DOI: 10.1186/s12878-019-0139-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
15 Yun JW, Yoon J, Kim JW, Kim S, Jung CW, Kim H. Isolated monocytosis was the flag preceding abnormalities in other parameters of complete blood counts in chronic myeloid leukemia with e1a2 (minor, P190) BCR-ABL1 chimeric transcripts. Precis Future Med 2019;3:30-5. [DOI: 10.23838/pfm.2019.00023] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]